BioMarin Pharmaceuticals BMRN Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| ALDURAZYME | $36.74M-25.6% | $49.39M-8.1% | $53.71M-4.8% | $56.44M+15.2% | $48.98M+25.5% | |
| BRINEURA | $47.1M-4.6% | $49.39M+3.0% | $47.95M-1.5% | $48.69M+20.6% | $40.36M-15.4% | |
| KUVAN | $23.88M+2.3% | $23.34M-2.9% | $24.03M-11.1% | $27.03M+7.6% | $25.14M-11.3% | |
| NAGLAZYME | $130.07M+8.2% | $120.22M-1.5% | $122.03M-5.3% | $128.87M+12.8% | $114.29M+3.9% | |
| PALYNZIQ | $89.56M-28.5% | $125.33M+15.2% | $108.78M+2.7% | $105.94M+13.6% | $93.27M-7.1% | |
| ROCTAVIAN | $2.64M-79.3% | $12.75M+301% | $3.18M-65.4% | $9.2M-12.5% | $10.51M-0.4% | |
| Royalty and other revenues | $6.13M-59.8% | $15.24M-0.5% | $15.32M+23.3% | $12.43M+18.4% | $10.5M-10.1% | |
| VIMIZIM | $210.2M+2.3% | $205.53M+12.5% | $182.76M-15.2% | $215.42M+14.4% | $188.35M-1.4% | |
| VOXZOGO | $219.88M-19.6% | $273.39M+25.2% | $218.39M-1.4% | $221.39M+3.6% | $213.75M+2.5% | |
| R&D by Product | ||||||
| Later-stage clinical programs | $36.18M+23.6% | $29.26M-88.4% | $251.65M+1,816% | $13.13M-8.1% | $14.29M+46.0% | |
| Marketed products | $55.33M-7.2% | $59.61M-7.0% | $64.11M+22.8% | $52.21M-3.3% | $53.97M-11.6% | |
| Research and early pipeline | $87.29M-15.7% | $103.55M+10.5% | $93.72M-2.3% | $95.97M+6.1% | $90.47M-11.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does BioMarin Pharmaceuticals break its business down?
- BioMarin Pharmaceuticals (BMRN) reports total revenues by product across 9 parts — ALDURAZYME, BRINEURA, KUVAN, NAGLAZYME and PALYNZIQ. Each is extracted from the segment footnotes and tracked over time.
- Where does BioMarin Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in BioMarin Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
